{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:32:42Z","timestamp":1790418762356,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Pediatric Neurology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.spen.2021.100877","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T21:12:33Z","timestamp":1612991553000},"page":"100877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Therapeutic Approaches for Duchenne Muscular Dystrophy: Old and New"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5571-7370","authenticated-orcid":false,"given":"Samuel J.","family":"Mackenzie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry R.","family":"Mendell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.spen.2021.100877_bib0001","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.spen.2021.100877_bib0002","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/ejhg.2012.301","article-title":"Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK)","volume":"21","author":"Moat","year":"2013","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.spen.2021.100877_bib0003","first-page":"195","article-title":"The natural history of Duchenne muscular dystrophy: A caveat for therapeutic trials","volume":"106","author":"Brooke","year":"1981","journal-title":"Trans Am Neurol Assoc"},{"key":"10.1016\/j.spen.2021.100877_bib0004","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0092-8674(95)90344-5","article-title":"Three muscular dystrophies: Loss of cytoskeleton-extracellular matrix linkage","volume":"80","author":"Campbell","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.spen.2021.100877_bib0005","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.nmd.2017.11.018","article-title":"Cognitive profile in Duchenne muscular dystrophy boys without intellectual disability: The role of executive functions","volume":"28","author":"Battini","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.spen.2021.100877_bib0006","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1479972307080697","article-title":"Mechanical ventilation in Duchenne patients with chronic respiratory insufficiency: Clinical implications of 20 years published experience","volume":"4","author":"Toussaint","year":"2007","journal-title":"Chron Respir Dis"},{"key":"10.1016\/j.spen.2021.100877_bib0007","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4187\/respcare.04025","article-title":"Decline in lung volume with Duchenne muscular dystrophy is associated with ventilation inhomogeneity","volume":"60","author":"Stehling","year":"2015","journal-title":"Respir Care"},{"key":"10.1016\/j.spen.2021.100877_bib0008","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/mus.25089","article-title":"Clinical trial readiness in non-ambulatory boys and men with Duchenne muscular dystrophy: MDA-DMD network follow-up","volume":"54","author":"Connolly","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.spen.2021.100877_bib0009","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11897-020-00456-0","article-title":"Duchenne muscular dystrophy: The heart of the matter","volume":"17","author":"Shih","year":"2020","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.spen.2021.100877_bib0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2021.100877_bib0011","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: Respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2021.100877_bib0012","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 3: Primary care, emergency management, psychosocial care, and transitions of care across the lifespan","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2021.100877_bib0013","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: The protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.spen.2021.100877_bib0014","first-page":"835","article-title":"Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications","volume":"45","author":"Den Dunnen","year":"1989","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.spen.2021.100877_bib0015","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/0888-7543(92)90437-W","article-title":"Construction of a 2.6-Mb contig in yeast artificial chromosomes spanning the human dystrophin gene using an STS-based approach","volume":"12","author":"Coffey","year":"1992","journal-title":"Genomics"},{"key":"10.1016\/j.spen.2021.100877_bib0016","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/338509a0","article-title":"Alternative splicing of human dystrophin mRNA generates isoforms at the carboxy terminus","volume":"338","author":"Feener","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.spen.2021.100877_bib0017","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","article-title":"Dystrophin and mutations: One gene, several proteins, multiple phenotypes","volume":"2","author":"Muntoni","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2021.100877_bib0018","doi-asserted-by":"crossref","first-page":"43-60","DOI":"10.1007\/s12035-011-8218-9","article-title":"Dystrophin Dp71: The smallest but multifunctional product of the Duchenne muscular dystrophy gene","volume":"45","author":"Tadayoni","year":"2012","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.spen.2021.100877_bib0019","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/348725a0","article-title":"Localization of dystrophin to postsynaptic regions of central nervous system cortical neurons","volume":"348","author":"Lidov","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.spen.2021.100877_bib0020","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/333861a0","article-title":"Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide","volume":"333","author":"Arahata","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.spen.2021.100877_bib0021","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM198807073190103","article-title":"Gastric hypomotility in Duchenne's muscular dystrophy","volume":"319","author":"Barohn","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2021.100877_bib0022","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0960-8966(94)90081-7","article-title":"Expression and subcellular localization of dystrophin in skeletal, cardiac and smooth muscles during the human development","volume":"4","author":"Chevron","year":"1994","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.spen.2021.100877_bib0023","doi-asserted-by":"crossref","first-page":"C651","DOI":"10.1152\/ajpcell.00244.2007","article-title":"Direct observation of failing fibers in muscles of dystrophic mice provides mechanistic insight into muscular dystrophy","volume":"294","author":"Claflin","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.spen.2021.100877_bib0024","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/j.2040-4603.2015.tb00638.x","article-title":"The Dystrophin complex: Structure, function, and implications for therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr Physiol"},{"key":"10.1016\/j.spen.2021.100877_bib0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1570-9639(02)00442-9","article-title":"New aspects of calcium signaling in skeletal muscle cells: Implications in Duchenne muscular dystrophy","volume":"1600","author":"Gailly","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.spen.2021.100877_bib0026","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/nm.3990","article-title":"Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division","volume":"21","author":"Dumont","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.spen.2021.100877_bib0027","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/humu.21114","article-title":"Mutational spectrum of DMD mutations in dystrophinopathy patients: Application of modern diagnostic techniques to a large cohort","volume":"30","author":"Flanigan","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.spen.2021.100877_bib0028","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/humu.20976","article-title":"Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: A model of nationwide knowledgebase","volume":"30","author":"Tuffery-Giraud","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.spen.2021.100877_bib0029","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD Global Database: Analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum Mutat"},{"key":"10.1016\/j.spen.2021.100877_bib0030","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","article-title":"An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus","volume":"2","author":"Monaco","year":"1988","journal-title":"Genomics"},{"key":"10.1016\/j.spen.2021.100877_bib0031","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ncl.2014.05.002","article-title":"Duchenne and Becker muscular dystrophies","volume":"32","author":"Flanigan","year":"2014","journal-title":"Neurol Clin"},{"key":"10.1016\/j.spen.2021.100877_bib0032","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM198906153202405","article-title":"Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy","volume":"320","author":"Mendell","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2021.100877_bib0033","first-page":"46572","volume":"86","author":"Gloss","year":"2016"},{"key":"10.1016\/j.spen.2021.100877_bib0034","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.23808","volume":"48","author":"Henricson","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.spen.2021.100877_bib0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mus.23807","article-title":"The cooperative international neuromuscular research group Duchenne natural history study\u2013a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used","volume":"48","author":"McDonald","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.spen.2021.100877_bib0036","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/mus.24346","article-title":"Outcome reliability in non-ambulatory boys\/men with Duchenne muscular dystrophy","volume":"51","author":"Connolly","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.spen.2021.100877_bib0037","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy","volume":"5","author":"Matthews","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.spen.2021.100877_bib0038","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.nmd.2018.07.004","article-title":"Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids","volume":"28","author":"McDonald","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.spen.2021.100877_bib0039","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2106\/00004623-200403000-00009","article-title":"Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy","volume":"86","author":"Alman","year":"2004","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.spen.2021.100877_bib0040","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jpeds.2013.05.060","article-title":"Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy","volume":"163","author":"Barber","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.spen.2021.100877_bib0041","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/1097-4598(200009)23:9<1344::AID-MUS4>3.0.CO;2-F","article-title":"A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy","volume":"23","author":"Bonifati","year":"2000","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.spen.2021.100877_bib0042","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","article-title":"Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy","volume":"87","author":"Griggs","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100877_bib0043","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: A prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.spen.2021.100877_bib0044","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/mus.26736","article-title":"Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent multicenter clinical trials","volume":"61","author":"McDonald","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.spen.2021.100877_bib0045","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaapos.2018.01.017","article-title":"Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients","volume":"22","author":"Rice","year":"2018","journal-title":"J AAPOS"},{"key":"10.1016\/j.spen.2021.100877_bib0046","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/mus.20646","article-title":"Weekly oral prednisolone improves survival and strength in male mdx mice","volume":"35","author":"Keeling","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.spen.2021.100877_bib0047","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1172\/JCI91445","article-title":"Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy","volume":"127","author":"Quattrocelli","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.spen.2021.100877_bib0048","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1016\/j.ajpath.2017.07.017","article-title":"Intermittent glucocorticoid dosing improves muscle repair and function in mice with limbgirdle muscular dystrophy","volume":"187","author":"Quattrocelli","year":"2017","journal-title":"Am J Pathol"},{"key":"10.1016\/j.spen.2021.100877_bib0049","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0960-8966(02)00180-3","article-title":"High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy","volume":"12","author":"Connolly","year":"2002","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.spen.2021.100877_bib0050","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1212\/WNL.0b013e318227b164","article-title":"Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy","volume":"77","author":"Escolar","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100877_bib0051","unstructured":"Finding the Optimum Regimen for Duchenne Muscular Dystrophy (FOR-DMD). Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01603407. Accessed September 10, 2020."},{"key":"10.1016\/j.spen.2021.100877_bib0052","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.nmd.2013.04.005","article-title":"Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: Results from the Muscular Dystrophy Association DMD Clinical Research Network","volume":"23","author":"Connolly","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.spen.2021.100877_bib0053","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/mus.26441","article-title":"Twice-weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy","volume":"59","author":"Connolly","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.spen.2021.100877_bib0054","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12883-019-1304-8","article-title":"Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry","volume":"19","author":"Cowen","year":"2019","journal-title":"BMC Neurol"},{"key":"10.1016\/j.spen.2021.100877_bib0055","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of genome size on AAV vector packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.spen.2021.100877_bib0056","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.spen.2021.100877_bib0057","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/mt.2009.254","article-title":"Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery","volume":"18","author":"Rodino-Klapac","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.spen.2021.100877_bib0058","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.spen.2021.100877_bib0059","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ymthe.2004.09.013","article-title":"Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contractioninduced injury","volume":"11","author":"Liu","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.spen.2021.100877_bib0060","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nm1439","article-title":"rAAV6microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice","volume":"12","author":"Gregorevic","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.spen.2021.100877_bib0061","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/mt.2008.28","article-title":"Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice","volume":"16","author":"Gregorevic","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.spen.2021.100877_bib0062","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/mt.2011.154","article-title":"AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice","volume":"19","author":"Bostick","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.spen.2021.100877_bib0063","doi-asserted-by":"crossref","first-page":"16105","DOI":"10.1038\/ncomms16105","article-title":"Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy","volume":"8","author":"Le Guiner","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.spen.2021.100877_bib0064","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: A nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.spen.2021.100877_bib0065","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.nmd.2017.02.007","article-title":"The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials","volume":"27","author":"Alfano","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.spen.2021.100877_bib0066","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160195","article-title":"Revised North Star Ambulatory Assessment for young boys with Duchenne muscular dystrophy","volume":"11","author":"Mercuri","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.spen.2021.100877_bib0067","article-title":"Long term natural history data in ambulant boys with Duchenne muscular dystrophy","volume":"1","author":"Pane","year":"2014","journal-title":"36-Month Changes"},{"key":"10.1016\/j.spen.2021.100877_bib0068","series-title":"Safety and Tolerability of PF-06939926 in Ambulatory Boys with Duchenne Muscular Dystrophy: A Phase 1b Multicenter, Open-Label","author":"Binks","year":"2020"},{"key":"10.1016\/j.spen.2021.100877_bib0069","series-title":"ACGST Annual Meeting","article-title":"SGT-001 microdystrophin gene therapy for Duchenne muscular dystrophy","author":"Gonzalez","year":"2020"},{"key":"10.1016\/j.spen.2021.100877_bib0070","doi-asserted-by":"crossref","first-page":"e81302","DOI":"10.1371\/journal.pone.0081302","article-title":"Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy","volume":"8","author":"Finkel","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.spen.2021.100877_bib0071","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"Bushby","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.spen.2021.100877_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.spen.2021.100877_bib0073","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2217\/cer-2019-0171","article-title":"Safety and effectiveness of ataluren: Comparison of results from the STRIDE Registry and CINRG DMD Natural History Study","volume":"9","author":"Mercuri","year":"2020","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.spen.2021.100877_bib0074","unstructured":"Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03179631. Accessed August 23, 2020."},{"key":"10.1016\/j.spen.2021.100877_bib0075","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.spen.2021.100877_bib0076","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2006.061","article-title":"Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle","volume":"18","author":"Arechavala-Gomeza","year":"2007","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.spen.2021.100877_bib0077","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","article-title":"Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: A single-blind, placebo-controlled, dose-escalation, proof-of-concept study","volume":"8","author":"Kinali","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2021.100877_bib0078","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping anddystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, doseescalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.spen.2021.100877_bib0079","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.spen.2021.100877_bib0080","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.spen.2021.100877_bib0081","doi-asserted-by":"crossref","first-page":"P1350","DOI":"10.1016\/S0140-6736(16)31765-2","article-title":"a balancing act","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.spen.2021.100877_bib0082","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1001\/jama.2016.16437","article-title":"Approving a problematic muscular dystrophy drug: Implications for FDA policy","volume":"316","author":"Kesselheim","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.spen.2021.100877_bib0083","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/nat.2018.0756","article-title":"A sequel to the eteplirsen saga: Eteplirsen is approved in the United States but was not approved in Europe","volume":"29","author":"Aartsma-Rus","year":"2019","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.spen.2021.100877_bib0084","doi-asserted-by":"crossref","first-page":"e15858","DOI":"10.1097\/MD.0000000000015858","article-title":"Longterm treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy","volume":"98","author":"Alfano","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.spen.2021.100877_bib0085","unstructured":"Study of Eteplirsen in DMD Patients (PROMOVI). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02255552. Accessed September 3, 2020."},{"key":"10.1016\/j.spen.2021.100877_bib0086","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100877_bib0087","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: A phase 2 randomized clinical trial","volume":"1","author":"Clemens","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.spen.2021.100877_bib0088","unstructured":"Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study. Available at: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeuticsannounces-positive-expression-results. Accessed August 28, 2020."},{"key":"10.1016\/j.spen.2021.100877_bib0089","doi-asserted-by":"crossref","first-page":"R163","DOI":"10.1093\/hmg\/ddy171","article-title":"Exon-skipping advances for Duchenne muscular dystrophy","volume":"27","author":"Echevarria","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.spen.2021.100877_bib0090","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ebiom.2019.06.036","article-title":"Peptideconjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases","volume":"45","author":"Tsoumpra","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.spen.2021.100877_bib0091","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1126\/science.1104297","article-title":"Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping","volume":"306","author":"Goyenvalle","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.spen.2021.100877_bib0092","unstructured":"AAV9 U7snRNA Gene Therapy to Treat Boys With DMD Exon 2 Duplications. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04240314. Accessed September 1, 2020."},{"key":"10.1016\/j.spen.2021.100877_bib0093","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy","volume":"351","author":"Long","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.spen.2021.100877_bib0094","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","article-title":"In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy","volume":"351","author":"Nelson","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.spen.2021.100877_bib0095","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.spen.2021.100877_bib0096","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.aau1549","article-title":"Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy","volume":"362","author":"Amoasii","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.spen.2021.100877_bib0097","unstructured":"A Safety and Efficacy Study Evaluating CTX001 in Subjects with severe sickle cell disease. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03745287. Accessed September 2, 2020."},{"key":"10.1016\/j.spen.2021.100877_bib0098","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/d41586-020-00655-8","article-title":"CRISPR treatment inserted directly into the body for first time","volume":"579","author":"Ledford","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.spen.2021.100877_bib0099","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1038\/s41467-018-05910-1","article-title":"NF-kappaB inhibition rescues cardiac function by remodeling calcium genes in a Duchenne muscular dystrophy model","volume":"9","author":"Peterson","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.spen.2021.100877_bib0100","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1212\/WNL.0000000000008168","article-title":"Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function","volume":"93","author":"Hoffman","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100877_bib0101","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3233\/JND-180341","article-title":"Phase 1 study of edasalonexent (CAT-1004), an oral NF-kappaB inhibitor, in pediatric patients with Duchenne muscular dystrophy","volume":"6","author":"Finanger","year":"2019","journal-title":"J Neuromuscul Dis"}],"container-title":["Seminars in Pediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107190912100005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107190912100005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:37:55Z","timestamp":1761028675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107190912100005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":101,"alternative-id":["S107190912100005X"],"URL":"https:\/\/doi.org\/10.1016\/j.spen.2021.100877","relation":{},"ISSN":["1071-9091"],"issn-type":[{"value":"1071-9091","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Approaches for Duchenne Muscular Dystrophy: Old and New","name":"articletitle","label":"Article Title"},{"value":"Seminars in Pediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.spen.2021.100877","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100877"}}